Velosef

Osteomyelitis, Peritonitis, Urinary Tract Infections + 5 more

Treatment

3 Active Studies for Velosef

What is Velosef

Cefradine

The Generic name of this drug

Treatment Summary

A type of antibiotic that is a combination of synthetic and naturally occurring ingredients.

Velosef

is the brand name

Velosef Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Velosef

Cefradine

1995

4

Effectiveness

How Velosef works in the body

Cefradine is an antibiotic that works by blocking the formation of bacterial cell walls. It attaches to proteins inside the cell wall and prevents it from fully forming. This causes the cell wall to break apart, leading to the death of the bacteria. It also might stop an enzyme from protecting the cell wall, making it even easier for the wall to break down.

When to interrupt dosage

The suggested dose of Velosef is contingent upon the diagnosed affliction, including Respiratory Tract Infections, Septic Arthritis and Sepsis Bacterial. The dosage amount oscillates based on the administration technique (e.g. Suspension or Capsule, gelatin coated - Oral) denoted in the table beneath.

Condition

Dosage

Administration

Urinary Tract Infections

500.0 mg, , 250.0 mg, 125.0 mg/mL, 250.0 mg/mL

Capsule, gelatin coated, , Oral, Capsule, gelatin coated - Oral, Suspension, Suspension - Oral

Osteomyelitis

500.0 mg, , 250.0 mg, 125.0 mg/mL, 250.0 mg/mL

Capsule, gelatin coated, , Oral, Capsule, gelatin coated - Oral, Suspension, Suspension - Oral

Peritonitis

500.0 mg, , 250.0 mg, 125.0 mg/mL, 250.0 mg/mL

Capsule, gelatin coated, , Oral, Capsule, gelatin coated - Oral, Suspension, Suspension - Oral

Respiratory Tract Infections

500.0 mg, , 250.0 mg, 125.0 mg/mL, 250.0 mg/mL

Capsule, gelatin coated, , Oral, Capsule, gelatin coated - Oral, Suspension, Suspension - Oral

Arthritis, Infectious

500.0 mg, , 250.0 mg, 125.0 mg/mL, 250.0 mg/mL

Capsule, gelatin coated, , Oral, Capsule, gelatin coated - Oral, Suspension, Suspension - Oral

Sepsis

500.0 mg, , 250.0 mg, 125.0 mg/mL, 250.0 mg/mL

Capsule, gelatin coated, , Oral, Capsule, gelatin coated - Oral, Suspension, Suspension - Oral

Sepsis

500.0 mg, , 250.0 mg, 125.0 mg/mL, 250.0 mg/mL

Capsule, gelatin coated, , Oral, Capsule, gelatin coated - Oral, Suspension, Suspension - Oral

Communicable Diseases

500.0 mg, , 250.0 mg, 125.0 mg/mL, 250.0 mg/mL

Capsule, gelatin coated, , Oral, Capsule, gelatin coated - Oral, Suspension, Suspension - Oral

Warnings

Velosef has two contraindications, hence it should not be taken when enduring any of the conditions delineated in the following table.

Velosef Contraindications

Condition

Risk Level

Notes

Bacterial Meningitis

Do Not Combine

known hypersensitivity to the drug or any of the ingredients

Do Not Combine

There are 20 known major drug interactions with Velosef.

Common Velosef Drug Interactions

Drug Name

Risk Level

Description

Abemaciclib

Major

The metabolism of Abemaciclib can be increased when combined with Cefradine.

Acalabrutinib

Major

The metabolism of Acalabrutinib can be increased when combined with Cefradine.

Alectinib

Major

The metabolism of Alectinib can be increased when combined with Cefradine.

Alpelisib

Major

The metabolism of Alpelisib can be increased when combined with Cefradine.

Aminophylline

Major

The metabolism of Aminophylline can be increased when combined with Cefradine.

image of a doctor in a lab doing drug, clinical research

Velosef Novel Uses: Which Conditions Have a Clinical Trial Featuring Velosef?

Currently, 15 active trials are being conducted to assess the potential of Velosef to combat Sepsis, Septic Arthritis and Peritonitis.

Condition

Clinical Trials

Trial Phases

Communicable Diseases

0 Actively Recruiting

Arthritis, Infectious

0 Actively Recruiting

Osteomyelitis

3 Actively Recruiting

Phase 2, Not Applicable

Respiratory Tract Infections

0 Actively Recruiting

Sepsis

0 Actively Recruiting

Sepsis

1 Actively Recruiting

Not Applicable

Peritonitis

0 Actively Recruiting

Urinary Tract Infections

0 Actively Recruiting

Velosef Reviews: What are patients saying about Velosef?

3.7

Patient Review

3/30/2010

Velosef for Acute Infection of the Nose, Throat or Sinus

image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about velosef

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is Velosef tablet used for?

"Velosef is an antibiotic used to treat bacterial infections. It is a cephalosporin type of antibiotic that belongs to the beta-lactam group of antibiotics and works by stopping the production of the bacterial walls."

Answered by AI

Is Velosef an antibiotic?

"Velosef is a semi-synthetic cephalosporin antibiotic. It comes in the form of capsules containing 250 mg and 500 mg cephradine, and a suspension containing 125 mg and 250 mg per 5 mL dose."

Answered by AI

What is Cefradine used to treat?

"Cefradine 500mg caps can help treat bacterial infections of the respiratory and urinary tracts, as well as the skin and soft tissues. This includes infections such as sinusitis, pharyngitis, tonsillitis, laryngo-tracheo bronchitis and otitis media."

Answered by AI

What are the side effects of Velosef?

"Stomach-related side effects like nausea, vomiting, and diarrhea are some of the most commonly reported problems with cephradine. A few people taking the drug have also developed a serious condition called pseudomembranous colitis."

Answered by AI

Clinical Trials for Velosef

Image of Ronald Reagan UCLA Medical Center in Los Angeles, United States.

Next Day Clinic for Patient Care

18+
All Sexes
Los Angeles, CA

The Next Day Clinic (NDC) is a quality improvement initiative that will be launched and operated by UCLA Health starting July 22, 2024. Its goals are to improve patient care and safety and to maximize cost effectiveness. The way it does this is by identifying patients in the ED who would normally be admitted for low-acuity conditions, and diverting them to a high-acuity clinic the following day called the NDC. This will help decompress the ED and the hospital, and allow for overall higher quality care. The Health System has partnered with UCLA's Healthcare Value Analytics and Solutions \[UVAS\] group which specializes in these types of program evaluations. The analysis conducted by the study team will be used to directly inform NDC operations, scaling, and future plans.

Recruiting
Has No Placebo

Ronald Reagan UCLA Medical Center

Image of Boston Medical Center in Boston, United States.

Recovery Management Checkups for Opioid Use Disorder

18 - 65
All Sexes
Boston, MA

This project is a pilot study of an adapted intervention of an existing Opioid Use Disorder (OUD) treatment retention intervention called Recovery Management Checkups (RMC). This intervention has been adapted to better fit the experiences and unique issues of those that have been hospitalized with serious injection related infections (SIRI) based on the findings from a prior qualitative study from the principal investigator. This project plans to test the adapted intervention within a smaller group of participants to assess feasibility, acceptability, and calculate early findings of intervention efficacy. Hospitalizations for SIRIs are a unique entry point for patients to start their recovery journey with medications for OUD (MOUD), but many people do not remain on long-term treatment, despite evidence that indicates MOUDs reduce death and re-hospitalization after SIRIs. The study objectives are to: * Assess the implementation feasibility of the adapted RMC model for patients with SIRI and OUD. * Establish preliminary estimates of intervention efficacy. * Make further adaptions to the intervention that will reduce both known and unknown barriers to care and increase effectiveness in future larger scale trials. Findings from this pilot study will result in further intervention refinement to better fit the target population, and serve as the basis for a larger randomized control trial that will have aims focused on more in-depth analysis of the efficacy of this program

Recruiting
Has No Placebo

Boston Medical Center

Simeon Kimmel, MD